Abstract
Objective: ONC201 is an orally bioavailable dopamine receptor 2 antagonist that has demonstrated antitumorigenic activity without significant toxicity in phase 1 and 2 trials. Thus, we evaluated the antitumorigenic effects of ONC201 in ovarian cancer (OC) cell lines and a high-grade serous OC mouse model [K18-gT121+/-; p53fl/fl; Brca1fl/fl (KpB)] using both obese and lean mice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
